Opinion|Videos|February 28, 2026

Considerations for integrating immunotherapy into earlier stages of bladder cancer

Fact checked by: Hannah Clarke

Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer.

In the following video, Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer (NMIBC). Scarpato is an associate professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee.